Oscar Health, Inc. (NYSE:OSCR) CAO Sells $146,050.24 in Stock

Oscar Health, Inc. (NYSE:OSCR) CAO Victoria Baltrus sold 8,078 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $18.08, for a total value of $146,050.24. Following the completion of the transaction, the chief accounting officer now owns 146,036 shares in the company, valued at $2,640,330.88. This represents a 5.24 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Oscar Health Stock Performance

Shares of NYSE:OSCR traded down $0.44 during midday trading on Tuesday, reaching $17.99. 6,121,611 shares of the company’s stock traded hands, compared to its average volume of 3,427,490. The company has a debt-to-equity ratio of 0.26, a quick ratio of 0.73 and a current ratio of 0.73. The company has a market cap of $4.45 billion, a price-to-earnings ratio of -307.12 and a beta of 1.64. The stock has a 50 day moving average of $17.33 and a 200 day moving average of $17.99. Oscar Health, Inc. has a one year low of $7.50 and a one year high of $23.79.

Oscar Health (NYSE:OSCR) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.02). Oscar Health had a return on equity of 2.79% and a net margin of 0.35%. The business had revenue of $2.42 billion during the quarter, compared to the consensus estimate of $2.33 billion. The firm’s revenue was up 68.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.29) earnings per share. As a group, equities research analysts anticipate that Oscar Health, Inc. will post -0.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on OSCR. Bank of America cut shares of Oscar Health from a “neutral” rating to an “underperform” rating and dropped their target price for the company from $21.00 to $13.50 in a research note on Wednesday, November 6th. UBS Group initiated coverage on Oscar Health in a research report on Monday, October 7th. They set a “neutral” rating and a $23.00 price target on the stock. Finally, Piper Sandler restated an “overweight” rating and issued a $28.00 price objective on shares of Oscar Health in a research note on Tuesday, September 10th. One analyst has rated the stock with a sell rating, two have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.93.

Institutional Investors Weigh In On Oscar Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Point72 Hong Kong Ltd purchased a new stake in shares of Oscar Health in the second quarter worth about $78,000. Quest Partners LLC purchased a new stake in shares of Oscar Health during the 2nd quarter worth approximately $93,000. KBC Group NV boosted its position in shares of Oscar Health by 41.2% during the 3rd quarter. KBC Group NV now owns 4,552 shares of the company’s stock valued at $97,000 after acquiring an additional 1,328 shares during the last quarter. Amalgamated Bank grew its holdings in shares of Oscar Health by 27.7% in the second quarter. Amalgamated Bank now owns 6,727 shares of the company’s stock valued at $106,000 after purchasing an additional 1,458 shares in the last quarter. Finally, Optimum Investment Advisors bought a new stake in Oscar Health in the third quarter worth $142,000. 75.70% of the stock is owned by hedge funds and other institutional investors.

Oscar Health Company Profile

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.